Millions are impacted by hearing loss. We're seeking to restore the clarity they've lost. LEARN MORE Reimagining Treatments for Hearing Loss More than 40 million people in the U.S. struggle with acquired sensorineural hearing loss, the most common type of hearing loss. This condition affects more than just hearing; it’s about communication and speech perception. Individuals may have difficulty speaking on the phone, struggle in school or at work and become socially isolated. What may start as a minor inconvenience can get progressively worse and is associated with other serious medical conditions like depression and dementia. Current treatments can help make sounds louder, but we’re leading the creation of the first-ever disease-modifying therapy for sensorineural hearing loss — one that aims to restore hearing function and enhance the ability to clearly understand speech. LEARN MORE Interested in joining our team? Explore careers © 2021 Frequency Therapeutics Open Positions Contact Privacy Policy Terms & Conditions

Skip to main navigation Utility PATIENTS CAREERS CONTACT US Investor Relations Corporate Profile Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells. Frequency’s hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss. Corporate Presentation Corporate Presentation - November 2021 Annual Report and Proxy Statement 2020 Annual Report 2021 Proxy Statement Stock Quote Nov 27, 2021 12:23 PM EST Change Today's Open Today's High Volume Previous Close Today's Low Stock VIEW MORE STOCK INFORMATION Recent News NOV 15 Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results NOV 9 Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis OCT 27 Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program News VIEW MORE NEWS Data Provided by Refinitiv. Minimum 15 minutes delayed. Interested in joining our team? Explore careers © 2021 Frequency Therapeutics Open Positions Contact Privacy Policy Terms and conditions